Onconova Therapeutics, Inc. (NASDAQ:ONTX) will hold its 3Q20 earnings conference call with the financial community on 12th November 2020 at 4:30 PM Eastern Time.
The conference call will be webcast live on Internet at www.onconova.com
Alternatively, callers may dial the number(s) (855) 428-5741 or (210) 229-8823 Outside U.S., with passcode : 8687160
Earnings Expectation
Onconova Therapeutics, Inc. clinical-stage biopharmaceutical firm, is expected to report third quarter earnings results, after market close, on Thursday 12th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.03 per share from revenue of $ 1.39 million. Looking ahead, the full year loss are expected at $ 0.13 per share on the revenues of $ 2.34 million.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.
